ONC Sales

[anonymous]

here’s a confidence boost for you. Merck has 980 clinical trials with pembro listed on clinical trials.gov

Combos with other classes of drugs and most every malignancy known.

But you’re talking about Merck. Who the heck really wants to work for them?

 

[anonymous]

no one for sure, but hard to see how Libtayo and it’s near orphan indication warrant a promotional expenditure.

Yeah it’s the backbone for other indications in combinations with other REGN antibodies, but those are years away from commercialization. As a stand alone Checkpoint inhibitor even combined with SOC chemo it’s got no legs.

 

[anonymous]

Merck just added another indication in NSCLC for Pembro. Total domination.

 

[anonymous]

This place is becoming a primary care gig on steroids. The micromanagement and the metrics are more than a typical big pharma company. Does anyone else feel that we are too small and territories too big to manage each of us this way?

 

[anonymous]

This place is becoming a primary care gig on steroids. The micromanagement and the metrics are more than a typical big pharma company. Does anyone else feel that we are too small and territories too big to manage each of us this way?

EXPANDING!

 

[ABC]

EXPANDING!

Elaborate on expanding!.............
I assume you mean we are hiring more reps. How many and when?

 

[ABC]

EXPANDING!

Elaborate on expanding!.............
I assume you mean we are hiring more reps. How many and when?

 

[anonymous]

Elaborate on expanding!.............
I assume you mean we are hiring more reps. How many and when?

Libtayo on fire. $27m for Q1, more people means more sales.

 

[anonymous]

RSD jobs posted in the west.

 

[anonymous]

RSD jobs posted in the west.

That's not an expansion. That's a backfill.

 

[anonymous]

I am shocked that anyone would leave this gig. Never had it so good.

 

[anonymous]

I am shocked that anyone would leave this gig. Never had it so good.

Good thing you aren’t selling Praluent

 

[anonymous]

That's not an expansion. That's a backfill.

Really? Did PJ leave?

 

[anonymous]

SGEN and Beigene hiring.

 

[anonymous]

big splash at ASCO.

 

[anonymous]

big splash at ASCO.

smoke and mirrors

 

[anonymous]

comic relief???

 

[anonymous]

Where is all the positive data coming out of ASCO? Quick Google search and you get 5 posts? This drug is setting world on fire.

 

[anonymous]

This is our first ASCO after the approval” of PD-1 inhibitor Libtayo, said E.B. Brakewood, VP and general manager of Regeneron’s oncology business unit. “This is anything but quiet. To us, this feels like the busiest ASCO ever.”

Spoken like a true rookie.

 

[anonymous]

This is our first ASCO after the approval” of PD-1 inhibitor Libtayo, said E.B. Brakewood, VP and general manager of Regeneron’s oncology business unit. “This is anything but quiet. To us, this feels like the busiest ASCO ever.”

Spoken like a true rookie.

another summer by the pool basking in our successful launch